CEL-SCI enters 50/50 revenue-sharing partnership with Amarox for Multikine in Saudi Arabia

CEL SCI CORP

50%/50% net revenue share for Multikine sales in Saudi Arabia; Amarox exclusive distributor upon SFDA approval.
Amarox ranked #1 for SFDA critical/unavailable medicine applications for 3 consecutive years (2022-2024).
Optional extension to GCC countries (Bahrain, Kuwait, Oman, Qatar, UAE). CEL-SCI retains all IP and global rights.
Partnership targets SFDA Breakthrough Medicine Designation for Multikine in head and neck cancer.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.